

Evidence dossier - DJE Kapital

GetCoattail manager profile: <https://getcoattail.com/manager/dje-kapital> | CIK 0001659196 | Rank #96 of 149 tracked managers by reported 13F value.

Background: Founded: 1974 | HQ: Pullach, Germany | Style: Value-oriented, risk-aware active asset management | Key person: Jens Ehrhardt

Background source: <https://www.dje.de/en-de/company/about-us/history/>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-04 Reported total value: \$5.3B Positions: 124 Top-10 concentration: 41.1% of reported value.

Ticker	Company	Weight	Reported value
LLY	Eli Lilly & Co	5.76%	\$306M
NVDA	Nvidia Corp	5.01%	\$266M
AMZN	Amazon Inc	4.78%	\$254M
GOOG	Alphabet Inc	4.51%	\$239M
LIN	Linde Plc	4.33%	\$230M
LRCX	Lam Research Corp	4.06%	\$215M
TSM	Taiwan Semiconductor-Sp Adr	3.93%	\$209M
MRK	Merck & Co. Inc.	3.53%	\$187M
TJX	Tjx Companies Inc	2.66%	\$141M
JNJ	Johnson & Johnson	2.53%	\$134M

2. Hypothetical 13F-clone results

Window: 2025-02-06 to 2026-10-02 (7 filings). Cumulative: +24.3% CAGR: +14.10% SPY same window: cumulative +29.4%, CAGR +16.91%. Trailing CAGR - 10Y: n/a, 5Y: n/a, 3Y: n/a, 1Y: +8.55%. Max drawdown (month-end, approximate): -8.1%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2024Q4	0001659196-25-000001	2025-02-06	129
2025Q1	0001659196-25-000003	2025-05-09	111
2025Q2	0001659196-25-000004	2025-08-07	105
2025Q3	0001659196-25-000006	2025-10-30	105
2025Q4	0001659196-26-000001	2026-02-12	108
2026Q1	0001659196-26-000002	2026-05-08	113
2026Q2	0001659196-26-000003	2026-08-04	124

4. Coverage and adjustments

Price coverage at the latest filing: 88.7% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.